Evenity (Romosozumab): How to Safely Stop and What Comes Next

What Romosozumab Actually Does in Your Body

Romosozumab works in a way no other osteoporosis drug does. It both builds new bone and slows bone breakdown at the same time, a dual action that makes it uniquely useful for women with very low bone density or a recent fracture.

The drug is a monoclonal antibody that targets sclerostin, a protein produced by osteocytes (the cells embedded in your bone matrix). Sclerostin normally acts as a brake on the Wnt signaling pathway, a molecular cascade that tells bone-forming osteoblasts to get to work. By binding and neutralizing sclerostin, romosozumab releases that brake. Osteoblasts activate and lay down new bone. At the same time, osteoclast-driven resorption decreases, though the exact mechanism for the antiresorptive side of the action is still being characterized.

The Dual-Effect Window

This dual effect is most pronounced in the first six months of treatment. Phase III data from the ARCH trial showed that lumbar spine bone mineral density (BMD) rose by roughly 13% over 12 months in the romosozumab group versus approximately 5% with alendronate. After about six months, the bone-building signal begins to taper even as the drug continues, which is one biological reason the course is capped at 12 doses rather than extended indefinitely.

Why a Fixed 12-Month Course

The FDA label sets a hard 12-dose ceiling because the anabolic window closes, and the cardiovascular signal observed in ARCH (discussed below) makes prolonged exposure unacceptable from a risk-benefit standpoint. According to the FDA-approved prescribing information, the course is one 210 mg subcutaneous injection per month for 12 months, delivered as two separate 105 mg injections given back-to-back at the same visit. There is no approved regimen beyond that.

What Happens to Your Bones When You Stop

Stopping romosozumab without follow-on therapy is one of the most important things your care team needs to plan for. The bone gain does not stay.

A post-hoc analysis of the FRAME trial showed that women who completed 12 months of romosozumab and then received no antiresorptive therapy lost approximately half the lumbar spine BMD they had gained within the following 12 months. By 24 months off drug, BMD was close to where it started. This is not unique to romosozumab. All anabolic agents share this "offset effect," but it is particularly sharp here because the drug was building bone so rapidly.

For a postmenopausal woman who started romosozumab because she had already fractured, sliding back toward her pre-treatment BMD means sliding back toward the fracture risk that made the drug necessary in the first place. This is why the prescribing information states explicitly that antiresorptive therapy should follow romosozumab.

The Offset Effect by Life Stage

For women in early postmenopause (roughly ages 50 to 60), bone turnover is still relatively high because estrogen withdrawal is recent. The offset effect may be somewhat faster in this group, though direct comparative data are limited. For women in late postmenopause, turnover is lower, and some data suggest a slightly slower BMD decline after stopping, but the difference is not large enough to justify skipping follow-on therapy.

The Required Transition: What to Take After Romosozumab

The month after your 12th injection, you need to start an antiresorptive drug. Your prescriber will choose based on your fracture history, kidney function, swallowing ability, adherence history, and whether you have been on prior osteoporosis therapy.

Bisphosphonates

Alendronate (Fosamax) and zoledronic acid (Reclast) are the two most common choices. In the ARCH trial, romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone over 24 months, the strongest fracture-reduction signal in a head-to-head osteoporosis trial at the time of publication. That result is the main reason sequential therapy (romosozumab first, bisphosphonate second) became the standard approach for high-risk postmenopausal women.

Zoledronic acid given as an annual intravenous infusion is preferred for women who have gastrointestinal issues, esophageal problems, or a history of poor oral bisphosphonate adherence. Oral alendronate 70 mg weekly is a reasonable choice when IV access is difficult or the patient prefers oral dosing.

Denosumab

Denosumab (Prolia) given as 60 mg subcutaneously every six months is an equally valid follow-on option. The FRAME trial used denosumab as the follow-on agent and demonstrated that women who transitioned from romosozumab to denosumab continued to gain lumbar spine BMD rather than losing it. If your prescriber chooses denosumab as follow-on, be aware that denosumab itself carries its own discontinuation hazard: stopping denosumab without a subsequent bisphosphonate can trigger a rapid, rebound increase in bone resorption and multiple vertebral fractures. The chain of sequential therapies matters.

What If You Cannot Take Either?

Raloxifene (Evista) and bazedoxifene are alternatives for women who cannot tolerate bisphosphonates or denosumab, but they provide weaker fracture protection and are generally not first-line follow-on choices after a high-risk drug like romosozumab. Abaloparatide and teriparatide are not appropriate follow-on options because they are also anabolic agents, and stacking two anabolic courses is not supported by evidence or guidelines.

How to Safely Stop Romosozumab: A Step-by-Step View

Stopping romosozumab is not complicated in the sense of needing a taper. The drug has a biological half-life of approximately 6.4 days, so it clears your system within four to five weeks of the last injection. You do not wean off romosozumab the way you might wean off a corticosteroid. The protocol is about what you start, not how you stop.

Step 1: Confirm Dose Count

Your care team should track the running total. After month 12, no further prescriptions should be written. If you are uncertain how many doses you have received, your pharmacy dispensing records and clinical notes will show the count.

Step 2: Schedule Your Follow-On Prescription

The antiresorptive should begin in the same calendar month as (or immediately after) the last romosozumab injection. A gap of even two to three months gives your osteoclasts room to begin erasing the gains. Ask your prescriber to have the follow-on drug in hand before you go to your final injection appointment.

Step 3: Confirm BMD Baseline

A dual-energy X-ray absorptiometry (DXA) scan after month 12 gives your team a post-treatment BMD to compare against follow-on therapy. The International Society for Clinical Densitometry recommends repeat DXA no sooner than every one to two years for monitoring, but a post-romosozumab DXA is clinically reasonable and provides a useful reference point.

Step 4: Address Calcium and Vitamin D

Hypocalcemia can occur during romosozumab treatment and is a contraindication to starting the drug. After stopping, calcium homeostasis typically normalizes. Your prescriber should confirm your calcium and 25-hydroxyvitamin D levels are adequate before and after the transition. Adequate calcium intake (approximately 1,200 mg per day from food and supplements combined for postmenopausal women per National Osteoporosis Foundation guidance) and vitamin D of at least 800 to 1,000 IU daily remain the backbone of osteoporosis care regardless of which drug you are on.

Step 5: Monitor for Osteonecrosis of the Jaw and Atypical Fractures

These risks are primarily associated with long-term antiresorptive therapy, not with romosozumab itself. As you transition, discuss your planned follow-on duration, any upcoming dental procedures, and whether you need a "drug holiday" from bisphosphonates at some future point. This planning happens now, not later.

The five-step transition framework above (dose count, follow-on timing, BMD baseline, calcium and vitamin D status, and long-term monitoring plan) is a practical synthesis of FDA labeling, ARCH trial data, and ISCD monitoring guidance, designed specifically for the clinical handoff moment that many women's health resources skip over.

Cardiovascular Risk: The Black Box Warning You Need to Understand

Romosozumab carries a boxed warning for major adverse cardiovascular events (MACE), specifically heart attack and stroke. This warning exists because of an imbalance observed in the ARCH trial: in ARCH, 2.5% of women on romosozumab experienced a serious cardiovascular event versus 1.9% on alendronate over the 12-month treatment period.

The absolute difference was small, roughly six additional events per 1,000 women treated. Whether the signal reflects a true drug effect or baseline imbalance in cardiovascular risk between the two groups remains debated. The FRAME trial, which compared romosozumab with placebo, did not show the same signal.

Despite that uncertainty, the FDA's position is firm: romosozumab should not be prescribed to women who have had a heart attack or stroke within the preceding 12 months. If you had a cardiovascular event during or after your course of romosozumab, your care team needs to weigh this when choosing your follow-on antiresorptive.

For the majority of postmenopausal women with osteoporosis who do not have recent cardiovascular events, the fracture benefit is considered to outweigh the cardiovascular risk, but this is an individual conversation, not a blanket reassurance.

Who This Drug Is Right For, and Who Should Look Elsewhere

Romosozumab is specifically indicated for postmenopausal women with osteoporosis at high risk of fracture, defined as T-score of negative 2.5 or lower with a prior fragility fracture, or multiple risk factors consistent with very high fracture risk per the prescribing information.

Women Who Are the Best Candidates

• Postmenopausal women with a prior vertebral or hip fracture and T-score at or below negative 2.5
• Women who have tried a bisphosphonate and continue to fracture or fail to gain BMD
• Women with very low BMD (T-score below negative 3.0) who need rapid bone-building before a surgical procedure such as spinal fusion
• Women in their 60s or 70s with no history of heart attack or stroke in the past year

Women Who Should Use a Different Therapy

• Women who have had a heart attack or stroke within 12 months (boxed contraindication)
• Women with hypocalcemia (must be corrected first)
• Women who are pregnant or planning pregnancy (see below)
• Women in reproductive years without reliable contraception
• Women whose fracture risk is mild to moderate and who have not yet tried a bisphosphonate (romosozumab is generally a second-line or high-risk first-line option)

Romosozumab Across Life Stages

Postmenopause: The Approved Population

All key trial data for romosozumab come from postmenopausal women. In ARCH, the mean age was 74 years and all participants were postmenopausal. The FRAME trial enrolled postmenopausal women with T-scores between negative 2.5 and negative 3.5. If you are postmenopausal with high fracture risk, you are in the studied population.

Perimenopause

Romosozumab is not approved for perimenopausal women, and no trial data exist in this group. Bone loss accelerates sharply in the two to three years around the final menstrual period due to estrogen withdrawal, but the appropriate first response in perimenopause is typically menopausal hormone therapy (MHT), which has documented bone-protective effects and addresses multiple symptoms simultaneously. Romosozumab would not be prescribed to a perimenopausal woman except in extraordinary circumstances of severe pre-existing osteoporosis.

Premenopausal Women and PCOS

Premenopausal women are not an approved population. Women with PCOS often have higher BMD than age-matched controls due to higher androgen and insulin levels, making osteoporosis less common in this group, though it is not impossible. No data support romosozumab use in premenopausal women outside of trials.

Pregnancy, Lactation, and Contraception

Romosozumab is contraindicated in pregnancy. This is a non-negotiable safety boundary. The Wnt signaling pathway that romosozumab activates plays a foundational role in fetal skeletal development. Animal studies showed fetal harm at exposures below the human therapeutic dose. There are no human pregnancy data, but the mechanism alone is enough to classify this drug as pregnancy-incompatible.

The FDA has not assigned a formal letter pregnancy category under the old system (drugs approved after 2015 use the PLLR labeling framework instead). The prescribing information states that women of reproductive potential should use effective contraception during treatment and for at least five months after the last dose, reflecting the drug's half-life and a safety margin.

Lactation. No human data exist on romosozumab transfer into breast milk. Given its molecular weight as a monoclonal antibody (approximately 136 kDa), transfer into mature breast milk is expected to be low, but the absence of data means the drug is not recommended during lactation. The practical reality is that romosozumab's approved population is postmenopausal women, so this concern is uncommon in clinical practice. It is relevant only if a younger woman with severe premenopausal osteoporosis is being considered for off-label use.

Contraception requirement. Any woman of reproductive age who receives romosozumab off-label should use highly effective contraception throughout the 12-month course and for five months after the final injection.

The Evidence Gap: What We Do Not Know Yet

Women have historically been under-represented in cardiovascular trials, but in osteoporosis research, women are the primary population, so the evidence base here is unusually woman-centered. The ARCH and FRAME trials enrolled only women.

What is less clear: data in women younger than 50, data in non-postmenopausal populations, and long-term outcomes beyond the 24-month trial follow-up periods. The 48% vertebral fracture reduction in ARCH was observed over 24 months total (12 months romosozumab, 12 months alendronate), not over a decade the way some bisphosphonate data extend. Whether the fracture benefit persists with optimal follow-on therapy over five or ten years is an open question. Long-term real-world registry data are accumulating but not yet definitive.

The cardiovascular signal also remains incompletely explained. The 2024 position statement from The Menopause Society does not specifically address romosozumab, but does emphasize that cardiovascular risk assessment is essential before initiating any osteoporosis therapy in postmenopausal women. Applying that principle to romosozumab means a careful look at cardiovascular history before prescribing, not after.

Practical Questions Women Ask at the Last Injection Visit

At your 12th and final injection appointment, it is reasonable to ask your clinician:

• Which follow-on drug are we starting and when exactly?
• Should I schedule a DXA scan now, or wait 12 months?
• Are my calcium and vitamin D levels adequate for the transition?
• What dental work, if any, should I complete before starting a bisphosphonate?
• When should I expect my next fracture-risk reassessment?

Getting clear answers to these five questions before you leave that appointment closes the most common gap in romosozumab follow-through.